AFM13
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkin Lymphoma
Conditions
Hodgkin Lymphoma
Trial Timeline
May 1, 2015 → Jul 1, 2020
NCT ID
NCT02321592About AFM13
AFM13 is a phase 2 stage product being developed by Affimed for Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02321592. Target conditions include Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04101331 | Phase 2 | Completed |
| NCT02321592 | Phase 2 | Completed |
Competing Products
20 competing products in Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| YM155 + Rituximab | Astellas Pharma | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 2 | 52 |
| ONTAK | Eisai | Phase 2 | 52 |
| Tazemetostat | Eisai | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 1 | 33 |
| ME-401 | Kyowa Kirin | Phase 2 | 52 |
| Tirabrutinib | Ono Pharmaceutical | Phase 1 | 33 |
| ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| Nivolumab + Brentuximab vedotin | Ono Pharmaceutical | Phase 3 | 77 |
| ONO-7018 + ONO-7018 | Ono Pharmaceutical | Phase 1 | 33 |
| R-mabHDI and ABVD + ABVD | Eli Lilly | Phase 3 | 77 |
| Prednisone + Vinblastine + Doxorubicin (Adriamycin) + Gemcitabine | Eli Lilly | Phase 1/2 | 41 |
| gemcitabine | Eli Lilly | Phase 2 | 52 |
| gemcitabine + cisplatin + dexamethasone | Eli Lilly | Phase 2 | 52 |
| LY4152199 - IV | Eli Lilly | Phase 1 | 33 |
| R-mabHD + ABVD | Eli Lilly | Phase 2 | 52 |
| enzastaurin + placebo | Eli Lilly | Phase 3 | 77 |
| LY317615 | Eli Lilly | Phase 2 | 52 |